Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02720094 · ClinicalTrials.gov registry record · Phase 2
Injectable Cabotegravir Compared to TDF/FTC For PrEP in HIV-Uninfected Men and Transgender Women Who Have Sex With Men
A Phase 2 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 2
- Development phase
- 4,570
- Enrollment target
NCT02720094: Completed Phase 2 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT02720094 is a Phase 2 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 4,570 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (3336% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02720094, a Phase 2 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 4,570 participants
- Enrollment target
Study Summary
This study will evaluate the safety and efficacy of the injectable drug cabotegravir (CAB LA), for pre-exposure prophylaxis (PrEP) in HIV-uninfected cisgender men and transgender women who have sex with men (MSM and TGW).
Primary Outcome
All HIV infections included in this analysis have been reviewed and confirmed by an independent, blinded Endpoint Adjudication Committee (EAC).
Interventions
- DRUG CAB LA
- DRUG Cabotegravir Oral Tablet
- DRUG TDF/FTC tablets
- DRUG Placebo for TDF/FTC tablets
- DRUG Placebo for cabotegravir oral tablet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,570 participants |
| Start Date | 2016-12-19 |
| Est. Completion | 2025-03-31 |
| Phase | Phase 2 |
What the finished NCT02720094 record still lists
NCT02720094 is an interventional study that assigns participants to a tested intervention. Its 4,570 participants enrollment target places it among the larger protocols in the corpus, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (3336% higher).
The record links to 0 conditions, and to 5 interventions - of which CAB LA is the first listed.
NCT02720094 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02720094 about?
NCT02720094 is a clinical study titled "Injectable Cabotegravir Compared to TDF/FTC For PrEP in HIV-Uninfected Men and Transgender Women Who Have Sex With Men". This study will evaluate the safety and efficacy of the injectable drug cabotegravir (CAB LA), for pre-exposure prophylaxis (PrEP) in HIV-uninfected cisgender men and transgender women who have sex with men (MSM and TGW).
What is the current status of trial NCT02720094?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 4,570 participants. The study started on 2016-12-19. Estimated completion is 2025-03-31.
What interventions are being tested in trial NCT02720094?
The interventions under investigation include: CAB LA (DRUG), Cabotegravir Oral Tablet (DRUG), TDF/FTC tablets (DRUG), Placebo for TDF/FTC tablets (DRUG), Placebo for cabotegravir oral tablet (DRUG).
Who is sponsoring clinical trial NCT02720094?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02720094's enrollment target sits among peer trials
4,570 2nd of 2000 the highest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05768217 · 4,600 participants · NA
Community Resiliency Collective Efficacy Intervention
- NCT06702878 · 4,514 participants · Phase 3
Light-Activated Antimicrobial Therapy to Prevent Surgical Site Infections
- NCT06535139 · 4,630 participants · NA
ReMARK: Addressing Disparities in Rural HPV-related Cancer Prevention
- NCT06533111 · 4,500 participants · NA
Improving Surgical Patient Outcomes Through Implementation of a SemiStructured Intraoperative Anesthesia Handoff Tool
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI